Patents by Inventor Zhenhao Qi

Zhenhao Qi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-TUMOR GENE SIGNATURE FOR SUITABILITY TO IMMUNO-ONCOLOGY THERAPY
    Publication number: 20220363760
    Abstract: The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more genes of a pantumor inflammation gene panel. In some aspects, the method further comprises administering an I-O therapy to the subject. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.
    Type: Application
    Filed: May 29, 2020
    Publication date: November 17, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Peter M. SZABO, Lan ZHANG, Keyur H. DESAI, Neeraj ADYA, Zhenhao QI, Kim ZERBA, Scott Adams ELY, Saumya PANT, George A. GREEN
  • METHODS OF IDENTIFYING A SUBJECT SUITABLE FOR AN IMMUNO-ONCOLOGY (I-O) THERAPY
    Publication number: 20220259669
    Abstract: The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more of STAT1, IFN?, NECTIN2, and CSFIR. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 18, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Peter M. SZABO, Lan ZHANG, Keyur H. DESAI, Neeraj ADYA, Zhenhao QI, Alex GREENFIELD, George C. LEE, Scott Adams ELY, Saumya PANT, George A. GREEN
  • CELL LOCALIZATION SIGNATURE AND COMBINATION THERAPY
    Publication number: 20220233691
    Abstract: The present disclosure provides methods of identifying a subject suitable for an immuno-oncology (I-O) therapy comprising measuring the expression of one or more of STAT1, IFN?, NECTIN2, and CSF1R. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 28, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Peter SZABO, Lan ZHANG, Keyur H. DESAI, Neeraj ADYA, Zhenhao QI, Alex GREENFIELD, George C. LEE, Scott Adams ELY, Saumya PANT, George A. GREEN
  • T cell proteins and nucleotides encoding the same
    Patent number: 8168752
    Abstract: The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: May 1, 2012
    Assignee: Boehringer Ingelheim Pharmaceutical, Inc.
    Inventors: Jianfei Yang, Frank James King, Jun Li, Zhenhao Qi, Ming Xue
  • CD38 splice variants and uses thereof
    Patent number: 7951933
    Abstract: The invention provides for a substantially purified polypeptide referred to herein as CD38JL that is a CD38 splice variant comprised of the polypeptide of SEQ ID NO: 1 or a fragment thereof. The invention also provides methods for treating preventing and diagnosing disorders associated with expression of CD38JL.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: May 31, 2011
    Assignee: Boehringer Ingelheim Pharmaceutical, Inc.
    Inventors: Jun Li, Xiang Li, Baerbel LoSacco, Zhenhao Qi
  • CD38 splice variants and uses thereof
    Publication number: 20050202482
    Abstract: The invention provides for a substantially purified polypeptide referred to herein as CD38JL that is a CD38 splice variant comprised of the polypeptide of SEQ ID NO: 1 or a fragment thereof. The invention also provides methods for treating preventing and diagnosing disorders associated with expression of CD38JL.
    Type: Application
    Filed: February 10, 2005
    Publication date: September 15, 2005
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Jun Li, Xiang Li, Baerbel LoSacco, Zhenhao Qi